|
Delayed
Sao Paulo
03:50:38 26/08/2026 HKT
|
5-day change | 1st Jan Change | ||
| 63.72 BRL | +1.43% |
|
+2.51% | +11.15% |
| 08-25 | Wall Street Wants Receipts |  |
| 08-25 | Lakefront Biotherapeutics, Gilead Secure Another Orphan Drug Designation for Skin Disorder Drug in US | MT |
| Market Cap | 184B 952B 158B 149B 136B 256B 17,594B 257B 1,759B 682B 8,876B 693B 678B 29,399B | P/E 2026 * |
-45.5x | P/E 2027 * | 18.5x |
|---|---|---|---|---|---|
| Enterprise Value | 201B 1,038B 173B 162B 148B 279B 19,191B 281B 1,918B 743B 9,682B 755B 739B 32,068B | EV / Sales 2026 * |
6.56x | EV / Sales 2027 * | 5.92x |
| Free-Float |
99.88% | Yield 2026 * |
2.22% | Yield 2027 * | 2.28% |
Last Transcript: Gilead Sciences, Inc.
| 1 day | +1.43% | ||
| 1 week | +2.51% | ||
| Current month | +15.30% | ||
| 1 month | +15.67% | ||
| 3 months | +13.41% | ||
| 6 months | +1.10% | ||
| Current year | +11.15% |
| 1 week | 61.56 |  | 63.93 |
| 1 month | 54.33 | | 64.18 |
| Current year | 52.08 | | 66.06 |
| 1 year | 48.98 | | 66.06 |
| 3 years | 27.26 | | 66.06 |
| 5 years | 22.04 | | 66.06 |
| 10 years | 17.05 | | 66.06 |
| Manager | Title | Age | Since |
|---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 61 | 01/03/2019 |
Andrew Dickinson
DFI | Director of Finance/CFO | 56 | 01/11/2019 |
Keeley Wettan
CMP | Compliance Officer | - | 18/12/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kelly Kramer
BRD | Director/Board Member | 58 | 19/08/2016 |
| Director/Board Member | 73 | 01/01/2018 | |
Harish Manwani
BRD | Director/Board Member | 72 | 09/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.43% | +2.51% | - | - | 184B | |
| -3.29% | -6.79% | +62.14% | +115.45% | 1,100B | |
| -1.11% | -1.39% | +52.77% | +64.11% | 658B | |
| -1.65% | -1.82% | +25.33% | +77.12% | 470B | |
| -1.47% | +0.24% | +42.09% | +42.12% | 372B | |
| -0.90% | +0.05% | +25.57% | +40.59% | 304B | |
| -1.94% | +1.53% | +3.05% | +13.24% | 264B | |
| -0.24% | -0.31% | +52.29% | +71.90% | 239B | |
| -0.93% | +1.84% | -13.11% | -52.83% | 213B | |
| -0.16% | +0.62% | +29.42% | +92.77% | 184B | |
| Average | -0.99% | +3.01% | +31.06% | +51.61% | 422.54B | |
| Weighted average by Cap. | -1.59% | +2.21% | +40.58% | +68.35% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 30.69B 158B 26.34B 24.73B 22.58B 42.62B 2,927B 42.83B 293B 113B 1,477B 115B 113B 4,892B | 32.7B 169B 28.06B 26.34B 24.06B 45.4B 3,118B 45.62B 312B 121B 1,573B 123B 120B 5,211B |
| Net income | -4.27B -22.06B -3.67B -3.44B -3.15B -5.94B -408B -5.96B -40.75B -15.79B -206B -16.05B -15.7B -681B | 10.28B 53.02B 8.82B 8.28B 7.56B 14.27B 980B 14.34B 97.96B 37.96B 494B 38.58B 37.74B 1,638B |
| Net Debt | 16.75B 86.4B 14.37B 13.49B 12.32B 23.25B 1,597B 23.36B 160B 61.87B 806B 62.87B 61.51B 2,669B | 9.12B 47.08B 7.83B 7.35B 6.71B 12.67B 870B 12.73B 86.99B 33.71B 439B 34.26B 33.52B 1,454B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25/08/26 | R$63.72 | +1.43% | 444 |
| 24/08/26 | R$62.82 | +0.27% | 444 |
| 21/08/26 | R$62.65 | +0.16% | 1,344 |
| 20/08/26 | R$62.55 | -2.02% | 206 |
| 19/08/26 | R$63.84 | +2.70% | 44 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GILD Stock
- GILD34 Stock
Select your edition
All financial news and data tailored to specific country editions
